It emerged yesterday that it replaced the two top executives at its Avexis unit, which conducted the preclinical development stages of the drug when the data manipulation allegedly happened.

Novartis’ AveXis unit has given its reasons for refusing to supply its spinal muscular atrophy gene therapy Zolgensma to a seriously ill child in Belgium, saying compassionate use rules do no ...

North Carolina economic development officials have terminated an economic incentives agreement for Novartis Gene Therapies, which hasn’t met hiring targets tied to a package that promised up to $1.5 ...

The pharmaceutical company says it will continue to operate its production facility near Research Triangle Park.

At the event, AveXis Scientific Founder and Chief Scientific Officer Brian Kaspar will discuss a revolutionary, single dose gene therapy that has been developed to treat the root cause of spinal ...

Austen Hufford covered national economics for The Wall Street Journal in Washington.

AveXis, a company that Novartis acquired and later renamed Novartis Gene Therapies, selected Durham for a $55 million manufacturing facility in 2018. The company a year later announced an ...

At AveXis, a Novartis company, we have built on 30 years of science to deliver on this challenge by demonstrating the long-term curative potential of gene therapy and its capacity to make an ...